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Christian de Duve first coined the expression “autophagy” during his seminal work on the
discovery of lysosomes, which led to him being awarded the Nobel Prize in Physiology or
Medicine in 1974. The term was adopted to distinguish degradation of intracellular com-
ponents from the uptake and degradation of extracellular substances that he called “het-
erophagy”. Studies until the 1990s were largely observational/morphological-based until in
1993 Yoshinori Oshumi described a genetic screen in yeast undergoing nitrogen depriva-
tion that led to the isolation of autophagy-defective mutants now better known as ATG
(AuTophaGy-related) genes. The screen identified mutants that fell into 15 complemen-
tation groups implying that at least 15 genes were involved in the regulation of autophagy
in yeast undergoing nutrient deprivation, but today, 41 yeast ATG genes have been
described and many (though not all) have orthologues in humans. Attempts to identify the
genetic basis of autophagy led to an explosion in its research and it's not surprising that in
2016 Yoshinori Oshumi was awarded the Nobel Prize in Physiology or Medicine. Our aimn, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, Glasgow
lasgow, Glasgow, G128TA, UK.
RS UMR 8104, Paris-Descartes University, 27, rue du Faubourg-Saint-Jacques, 75014 Paris,
gow.ac.uk (M.M. Harnett), gordon.langsley@inserm.fr (G. Langsley).
g Gung University.
ublishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND
s/by-nc-nd/4.0/).
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week), but to celebrate Yoshinori Oshumi's Nobel Prize by highlighting just a few aspects
that are not normally extensively covered. In an accompanying mini-review we address
the role of autophagy in early-diverging eukaryote parasites that like yeast, lack lysosomes
and so use a digestive vacuole to degrade autophagosome cargo and also discuss how
parasitized host cells react to infection by subverting regulation of autophagy.autophagosome biogenesis during selective autophagy, where
Induction of autophagy: the ATG1/ULK1/2
initiation complex and the increasingly
controversial roles of ATGs
Traditionally, starvation has been the classical way to stim-
ulate autophagy [Fig. 1], since degradation of autophagosome
cargo by lysosomes generates nutrients that enable the cell to
survive until fresh “food” comes on-line [1]. Consistent with
nutrient sensing being a key regulator of autophagy, when
rapamycin (inhibitor of mTOR) treatment was found to pro-
mote the translocation of the ULK1 complex from the cytosol
to certain domains of the endoplasmic reticulum (ER) (or
closely attached structures) and induce autophagy [2,3], the
role of mTORC1 kinase-mediated phosphorylation of the
ATG1/ULK1/2 complex (ULK1/2, ATG13, FIP200 and ATG101) in
suppressing induction of autophagy when nutrients (for
example amino acids) are abundant, became clear [4e6]. By
contrast, upon energy restriction, ULK1 is activated via
phosphorylation by AMP-activated kinase (AMPK) that at the
same time phosphorylates and inhibits mTORC1 [7,8]. More-
over, in addition to phosphorylation-mediated activation,
ULK1-induction also occurs upon acetylation in response to
amino acid, glucose, or growth factor deprivation [9]. How-
ever, the ever-expanding roles of autophagy in other cellular
processes (differentiation [10], clearing of aberrant aggregates
and damaged organelles [11], metabolism [12], innate and
adaptive immunity [13e15] e see below) over and above
nutrient deprivation has led to the realisation that there are
ways of inducing autophagy independent of the ATG1/ULK1/2
complex. In addition, many early-diverging eukaryote para-
sites lack genes orthologous to ATG1 (see accompanying mini
review), yet they still induce autophagy.
Further complicating matters, recent studies [16] have also
challenged the orthodoxy that the ATGs (ATG3/AT5/ATG7)
involved in lipid conjugation of ATG8/LC3 drive autophago-
some formation in mammals by showing that mouse em-
bryonic fibroblasts (MEF) lacking ATG-3, -5 or -7 (but not
upstream elements ATG14 or FIP200) were still capable of
forming isolation membranes. However, their ability to
generate mature closed autophagosomes was impaired sug-
gesting that these ATG elements may act to promote auto-
phagosome closure and consequent degradation of the inner
autophagosomal membrane, invoking a mechanism of in-
ward fission by which vesicular enzymes can degrade mem-
branes [16,17]. Interestingly, a role has previously also been
suggested for LC3 in autophagosome closure and fusion with
lysosomes [18]. The new studies were performed under basal
or starvation conditions and so they do not necessarily rule
out a role for the ATG lipid conjugation system inLC3-II is crucial for tethering specific cargoes for degradation
[17]. Nevertheless, together with the increasing realisation of
roles for ATG proteins both in non-canonical mechanisms of
autophagy and also in functions completely independent of
autophagy [14,19e21], care should be taken with genetic
studies implicating the mechanistic involvement of auto-
phagy on the basis of disruption of ATG signalling.The type III phosphatidylinositol 3-kinase Vps34
Activation of ULK1/ATG1 cooperates with Vps34 in autophagy
initiation. Vps34 is usually found dimerized to Vps15, but a
second complex including Beclin 1 (ATG6) is abundant in
mammalians cells. Furthermore, Vps34/Vps15/Beclin 1 can
form a tetramer complex with either ATG14 (complex I), or
with UVRAG/Vps38 (complex II), where complex I regulates
autophagosome formation and complex II the fusion of
autophagosomes with lysosomes [22]. In the early steps of
starvation-induced autophagy, VMP1-Beclin 1-mediated pro-
duction of PIP3 in the ER [4,23,24], recruits double-FYVE-
domain containing protein 1 (DFCP1) to the so-called omega-
some, which is an autophagosomal precursor to allow coop-
eration withWD-repeat domain phosphoinositide-interacting
(WIPI)-2, that promotes development of omegasomes into
isolationmembranes or autophagosomes [25]. EEA1 is another
FYVE-domain protein that is involved in Rab5 and Rab7 acti-
vation on early and late endosomes, the latter of which plays a
key role in the maturation of autophagosomes and in auto-
phagosome fusion with lysosomes [26]. As Ohsumi's original
genetic screen was measuring cytosol to vacuole transport
(cvt), the finding that some Rabs, small GTPases that regulate
vesicular traffic, are also involved in regulating vacular pro-
tein sorting (Vps) is not unexpected and today, in addition to
the aforementioned Rab5 and Rab7, several other Rabs (Rab1,
Rab9A, Rab11, Rab23, Rab32, and Rab33B) and Rab-effector
proteins are known to participate in autophagosome forma-
tion and autophagosome maturation [27e29].cAMP-dependent PKA and autophagy regulation
Over 10 years ago using the yeast, Saccharomyces cerevisiae it
was demonstrated that the cAMP-dependent PKA signalling
pathway is involved in controlling autophagy [30]. Interest-
ingly, ATG1, ATG13 and ATG18, were all identified as potential
substrates for PKA and PKA-mediated phosphorylation of
ATG1 regulated its association with the pre-autophagosomeal
Fig. 1 The molecular events involved in membrane initiation, elongation and completion of the autophagosome. The major
membrane source of the autophagosome is thought to be the endoplasmic reticulum (ER), as electron tomography has
demonstrated a direct connection with ER cisternae and autophagosomal membranes [164,165]. However, and as evidenced by
ATG9, a multispanning membrane protein that traffics between the trans-Golgi network, endosomes and autophagosome
precursors being shown to be essential for autophagy [166], several additional sources (mitochondrial, plasma and nuclear)
have been implicated [71,167,168]. Following induction of autophagy, the ULK1 complex (ULK1-ATG13-FIP200-ATG101)
translocates to the ER and transiently associates with vacuole membrane protein 1 (VMP1) resulting in the activation of the
class III PI3K, Vps34 and recruitment of the double FYVE domain-containing protein (DFCP1), WD repeat domain
phosphoinositide-interacting protein 2 (WIPI2) and the ATG12-ATG5-ATG16L1 complex to the outer surface of the isolation
membrane. Elongation of the isolation membrane requires the sequential action of the protease ATG4, the E1-like enzyme
ATG7 and the E2-like enzyme ATG3 to generate, via the E3-like activity of the ATG5-ATG12-ATG16 complex, the
phosphatidylethanolamine (PE)-conjugated form of microtubule-associated protein light chain 3 (LC3-II; a homolog of yeast
ATG8). This is associated with both the outer and inner membrane of the isolation membrane where it can tether the
autophagic cargo to the isolation membrane through specific adaptor proteins such as p62/SQSTM1, that bind
polyubiquitinylated protein aggregates targeting them for degradation in the autolysosomes, through its association with LC3-
II in the forming autophagosome [63]. The mechanisms of autophagosome closure and fusion are less clear but it has been
proposed that ATG proteins and LC3 may play an important role in closure of the autophagosome [16e18]. Following
dissociation of ATG16, dynein may be recruited via interaction with LC3 to promote trafficking to the perinuclear region of the
cell for fusion with lysosomes [18].
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candidate PKA regulators of different steps of autophagy were
identified demonstrating that cAMP-fluxing and phosphory-
lation via PKA has a profound impact on regulation of auto-
phagy [32].
Thus, in mammalian cells (originally neurones) the ATG8
orthologue LC3 was found to be phosphorylated by PKA at S12
and this reduced LC3 recruitment to autophagosomes, illus-
trating that similarly to the yeast system, a rise in cAMP levelsthat activates PKA diminishes autophagy [33]. This led to the
proposal of the existence of a pool of pre-phosphorylated LC3
that gets rapidly recruited to autophagosomes in response to
nutrient deprivation or mitochondrial injury with dephos-
phorylation of LC3 allowing cells to rapidly switch from basal
to induced autophagy.
A special type of autophagy is called mitophagy, where
damaged mitochondria are degraded and this process is
regulated by PINK1 (PTEN-induced putative kinase 1) and
b i om e d i c a l j o u r n a l 4 0 ( 2 0 1 7 ) 9e2 212Parkin, so called because mutations in these genes are
involved in Parkinson's disease [34]. PINK1 recruits the ubiq-
uitin ligase Parkin to damaged mitochondria that become
polyubiquitylated and degraded by mitophagy. Raising cAMP
levels by forskolin stimulation of adenylate cyclase, or over-
expression of PKA both inhibited recruitment of Parkin to
depolarized mitochondria, again consistent with cAMP-
dependent PKA acting as a negative regulator of autophagy,
in this case mitophagy [35]. A mitochondrial membrane pro-
tein MIC60 is phosphorylated by PKA at S528 and PKA-
mediated phosphorylation of MIC60 blocks assembly of the
PINK1 complex and loss of PINK1 on mitochondria.
Oxidative stress induces both autophagy and an anti-
oxidant transcriptional response mediated by the Nrf2 tran-
scription factor: coordination of these processes is mediated,
at least in part by the scaffold protein p62/SQSTM1 that links
autophagy to Keap1, an adapter of the ubiquitin ligase com-
plex that (negatively) regulates Nrf2 [36]. mTORC1-dependent
phosphorylation of p62 on S351 causes greater p62 affinity for
Keap1 and as a consequence, Keap1 together with phosphor-
ylated p62 is degraded by autophagy and Nrf2 is stabilized and
can translocate to the nucleus to transcribe anti-oxidant
genes. PKA also phosphorylates p62, but at S24 interfering
with its ability to homopolymerise and initiate autophagy,
indicating again how cAMP-dependent PKA can act as a
negative regulator of autophagy [37]. In yeast there is a large
(circa 500 proteins) network of potential PKA regulators [32]
and therefore, there are many potential ways for cAMP-
dependent PKA to act as a negative regulator of autophagy.Stress activated c-Jun N-terminal Kinase (JNK)
and regulation of autophagy
At the time of writing a key word search “JNK & autophagy”
identified over 500 papers in PubMed, so we will not try to
review the ensemble contribution of JNK to autophagy, but
just highlight a few examples. As discussed above, Parkin and
PINK1 mutations are associated with Parkinson's disease, but
a third gene coding for DJ-1 also known as PARK7 is mutated
[34,38]. DJ-1/PARK7 is a member of the C56 peptidases that
function as sensors and modulators of reactive oxygen spe-
cies, so it's not surprising that a stress activated kinase like JNK
is involved in mediating DJ-1/PARK7's effect on autophagy. In
normal growth conditions DJ-1/PARK7-regulated autophagy
involves JNK due to DK-1/PARK7 binding directly to MEKK1 to
regulate JNK activity and increase c-Jun-driven Beclin 1 tran-
scription [39,40]. Beclin 1 (BECN1) is the mammalian ortho-
logue of ATG6 and Beclin 1 can interact with either Vps34 [41],
or mitochondrial located Bcl-2, and because of this Beclin 1
plays a critical role in the regulation of both autophagy and cell
death. Thus, in Parkinson's disease, loss of DJ-1/PARK7 would
result in reduced JNK and c-Jun signalling, ablated BECN1
expression and dampened Vps34 activity, contributing to
reduced autophagic clearing of damage mitochondria.
When autophagy is induced by nutrient deprivation Bcl-2
only weakly binds to Beclin 1, but under conditions where
autophagy is inhibited by nutrient excess, binding to Beclin 1
is increased [42]. This reflects that upon nutrient deprivation
multi-site phosphorylation of Bcl-2 leads to disruption of theBcl-2/Beclin 1 complex resulting in “liberation” of Beclin 1 to
form a complex with Vps34 and Vps15 and induce autophagy
[41]. JNK1 signalling is responsible for the multi-site phos-
phorylation of Bcl-2 and as a consequence JNK1 signalling
promotes autophagy [43]. However, as yeast lack a Bcl-2
orthologue this mode of autophagy induction is specific to
mammalian cells. Since diverse stress stimuli trigger JNK1-
mediated autophagy it argues that the different cellular
stress-response programmesmediated by JNK1 signalling and
regulation of autophagy are intricately intertwined [43].
The second JNK isoform JNK2 promotes stressed-induced
mitophagy, but in contrast to JNK1 that targets Bcl-2, JNK2
directs the small mitochondrial form of ARF (smARF) for
degradation [44]. smARF is a short isoform of the tumour
suppressor ARF that localizes exclusively to mitochondria,
whose abundance in steady-state conditions is extremely low
due to constant degradation by the proteasome [45]. By
exploiting MEFs deleted for jnk1 and jnk2 one observes that
loss of JNK2, but not JNK1, leads to stabilization of smARF, but
interestingly, the kinase activity of JNK2was not necessary for
the increase in smARF abundance. Rather, mitochondria-
located JNK2 appears to act as a scaffold that promotes the
ubiquitylation and proteasomal degradation of smARF via an
unknown mechanism that involves p62/SQSTM1, since in
jnk2/ MEFs lysosomal degradation of p62/SQSTM1 is
enhanced [45]. Increased levels of JNK2 thus protect p62 from
degradation to promote mitophagy, while promoting degra-
dation of smARF.
In addition to being involved in autophagy due to its LIR
(LC3-interacting region), KIR (Keap1-interacting region) and
UBA (ubiquitin-associated) domains (as discussed above), p62/
SQSTM1 also has PB1 (Phox and Bem1), Zn (zinc finger) and TB
(Traf6 binding) domains allowing it to participate in diverse
signalling pathways [46]. One new pathway is Wnt/planar cell
polarity (PCP) signalling due to the core component VANGL2
being able to bind p62/SQSTM1 [47]. Cancer cells have long
been known to suppress autophagy and as VANGL2 expres-
sion is unregulated in breast cancer, it's binding of p62/
SQSTM1 might have been expected. However, counter-
intuitively, VANGL2 recruits, and promotes the phosphoryla-
tion of, JNK leading to c-Jun-driven transcription of BECN1 and
augmented Beclin 1 and eventually, greater Vps34 activity that
would induce autophagy (as discussed above). However, JNK
binding to VANGL2 was shown to occur close to the LC3
recruitmentmotif [47,48] and although not examined, it raises
the possibility that VANGL2 binding to p62/SQSTM1 ablates
LC3 recruitment to block autophagy and this would provide a
molecular rationale for unregulated VANGL2 expression in
breast cancer. Clearly, due to the multi-binding motif char-
acter of p62/SQSTM1 this scaffold is involved in many sig-
nalling pathways over and above its role in autophagy and
caution is therefore required in pronouncing on specific p62/
SQSTM1 functions.Autophagy: infection versus inflammation?
Ancient organisms likely exploited autophagy as a primordial
protective mechanism against pathogens that depleted
cellular nutrients before evolving, in parallel with
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based defence processes termed ‘xenophagy’, to clear bacte-
ria, parasites and viruses by targeting pathogen-containing
phagocytic vacuoles for autophagolysosomal destruction
[14,49]. Reflecting the evolutionary versatility of these pro-
cesses, whilst the diameter of autophagosomes involved in
metabolic turnover are typically 0.5e1.5 mm in diameter [50],
group A Streptococcus-containing autophagosome-like vacu-
oles can be as large as 10 mm, due to the RAB7-dependent
fusion of small isolation membranes [51]. Nevertheless, such
evolution has resulted in integration of the autophagy ma-
chinery designed tomaintain homeostasis of cell metabolism,
function and survival with innate and adaptive immune
response networks. This allows efficient coordination of
pathogen-sensing and via phagolysosomal maturation, anti-
microbial activity; for example, the cell surface microbial
sensor, SLAM recruits the Beclin 1/class III phosphoinositide
3-kinase (PI3K) complex to phagosomes containing Gram-
negative bacteria, facilitating phagolysosomal fusion and
activation of the anti-bacterial NADPH oxidase (NOX2) com-
plex [52]. Moreover, the generation of proinflammatory cyto-
kine responses and fusion of pathogen-containing
phagosomes with lysosomes to promote MHC class II antigen
presentation [53], links innate and adaptive immunity,
resulting in induction of protective cellular (Th polarisation)
and humoral responses.
Moreover, as increasingly recognised [14,19e21], compo-
nents of the autophagy machinery exhibit additional roles in
infection, either functioning independently of autophagy as in
the regulation of viral replication or alternatively, being
recruited to deal with pathogens in a non-canonical manner
that does not involve autophagosome formation as exempli-
fied by LC3-associated phagocytosis (LAP); exploitation of
ULK1/PI3K Class III complexes to form pathogen-containing
single or double membrane vacuoles or recruitment of IFNg
effector molecules to the parasitophorous vacuole. For
example, in macrophages infected with Toxoplasma gondii, the
parasite-derived membrane, termed the parasitophorous
vacuole, undergoes destruction through a mechanism that
involves ATG5-dependent recruitment of the IFNg effectors,
immunity-related GTPase proteins (IRGs) guanylate-binding
proteins (GBPs) leading to the death of the parasite-infected
cell [54e56].
Nevertheless, the mechanisms utilised by cells to target
pathogens such as intracellular bacteria to autophagolysoso-
mal compartments are notably similar to those utilised for the
selective autophagy of endogenous cargo. For example,
cellular cargo is directed to the autophagosomes bymolecular
tags (e.g. polyubiquitin) that are recognised by adaptor pro-
teins such as p62/SQSTM1 containing an LC3-interacting re-
gion (LIR; the core consensus sequence is [W/F/Y]xx[L/I/V], but
several unconventional sequences have also been described)
allowing them to deliver designated cargo to nascent LC3-
containing isolation membranes [49]. Likewise, ubiquitin-p62
signalling is required for the targeting of intracellular bacte-
ria such as Salmonella enterica serotype typhimurium (S. typhi-
murium), Shigella flexneri and Listeria monocytogenes to the
autophagosomes [57].
The various microbial-sensing mechanisms (NLRs, TLRs,
DAMPs, Cytokine Receptors) and cargo receptors (such as p62/SQSTM1, NBR1, NDP52, OPTN and TAX1BP1 that bind LC3) are
well described elsewhere [14,15,48,56,58e60]. Thus, we will
focus on how autophagy balances the need to clear pathogens
with its homeostatic resolution of inflammation to prevent
inflammatory disease, with emphasis on the counter-
regulatory TLR, inflammasome, and mTOR signalling that
impacts on autophagy function: in particular, we will describe
some of the mechanisms by which pathogens subvert the
autophagy machinery to evade the immune response and
hence may inform on potential targets to develop novel
therapies to treat aberrant inflammatory disorders and asso-
ciated comorbidities associated with metabolic syndrome
(obesity) and ageing.TLR-induced autophagy and its subversion by
pathogens
Autophagy plays key roles in TLR-associated immunity,
notably in killing of intracellular pathogens, antigen presen-
tation and T cell polarisation: however, this critical and
complex cellular homeostatic mechanism also controls
inflammation, acting to antagonise inflammasome signalling
and to limit and resolve inflammation [14,15,61,62]. TLR4 and
-7/8 mediate the strongest induction of autophagosome for-
mation [63], with TLR-dependent autophagy generally occur-
ring over 2e24 h, perhaps suggesting involvement of a
transcription programme to promote surveillance of infec-
tious agents that may have escaped into the cytosol [61,64].
Reflecting this, although the Gram-negative agent of tular-
aemia, Francisella tularensis that is recognised by, and acts to
subvert TLR2 signalling, escapes the phagosome, it can still be
targeted to autophagosomes due to its recognition by NALP3
(Nacht domain-, leucine-rich repeat-, and PYD-containing
protein 3), a member of the NOD-like receptor (NLR) family:
indeed, it has been suggested that such Pattern Recognition
Receptors (PRRs) can provide docking sites for the formation of
the isolation membrane [65]. Interestingly, therefore, in an
apparent mechanism to minimise the opportunities for mi-
croorganisms to subvert the phagosome, TLR-mediated
autophagosome formation can be more rapidly matured by
involvement of LAP, as this process appears to occur without
the formation of a double membrane phagophore [64]. TLR-
mediated autophagy can be further modulated by cytokines
with type I IFNs promoting autophagic clearance of viruses
such as HSV1, while IFNg can directly up-regulate autopha-
gosome formation for clearance of mycobacterium [63].
Autophagy is likewise generally promoted by TNFa (particu-
larly under conditions of low NF-kB activation) and Th-1 cy-
tokines, but antagonised by those produced by Th2 cells
[66,67].
Autophagy also contributes to antigen processing and
presentation, effectively linking innate and adaptive re-
sponses [13e15,59,68]. In particular, autophagy provides a
mechanism for targeting cytosolic antigens to MHC class II
molecules and explains why endogenous peptides from
cytosolic and nuclear proteins and viral antigens are
expressed on MHC class II molecules and elicit CD4þ T cell
responses [69,70]. Likewise, autophagy can enhance antigen
donor cell cross-presentation to CD8þ T cells [70], DC cross-
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and MHC class I presentation of intracellular antigens to
CD8þ T cells [71]. That TLR-stimulated autophagy is associ-
ated with enhanced autophagy-dependent display of peptides
on MHCII molecules is reflected by the ability of LPS (or
rapamycin to block mTOR) to promote presentation of
mycobacterial antigen on MHC class II molecules [72]. The
participation of autophagy in cross-presentation has also
been observed in vivo during HSV and Listeria infection [53] as
DC-specific deletion of ATG5 results in defects in priming of
CD4þ T-cell responses and mice succumb more rapidly to
lethal disease after intravaginal HSV infection. Analysis of
these DCs revealed defects in phagosome-to-lysosome fusion
and the cross presentation of MHC class II molecules of
phagocytosed antigens containing TLR ligand, despite the
ATG5-deficient DCs displaying normal migration, endocytic
and phagocytic activity and cross-presentation of peptides on
MHC class I molecules.
Nevertheless, whilst induction of autophagy is clearly
critical to the immune response to pathogens, the complex
signalling interplay between metabolic and inflammatory
pathways and autophagy has formany years shrouded its role
in TLR-mediated inflammation in controversy [14,15,73,74].
However, the increasing evidence that autophagy and
inflammasome signalling are counter-regulatory and inflam-
masomes can be degraded by autophagy [73,75,76], goes some
way to reconciling apparently contradictory data and in-
dicates that in addition to its anti-microbial actions, auto-
phagy plays critical roles in limiting pathological
inflammation and also in the homeostatic resolution of
inflammation following pathogen clearance. Thus, whilst the
TLR4 ligand, LPS is not generally sufficient, in the absence of
other signals such as ATP, to trigger inflammasome activation
in macrophages, it can induce inflammasome signalling in
macrophages deficient in ATG16L1 or ATG7 [73,75,77]. By
contrast, autophagy is enhanced in caspase 1 KO cells in
response to S. flexneri [78]. An intriguing example of how
pathogens can exploit such counter-regulation of autophagy
and inflammasome activation to evade the immune response
is provided by recent studies on Pseudomonas aeruginosa
[79,80]: thus, although recognition of P. aeruginosa induces
autophagy via TLR4 and its adaptor TRIF, this is suppressed by
the P. aeruginosa-mediated activation of the NLRC4 inflam-
masome resulting from its ROS-mediated release of mito-
chondrial DNA. Such NLRC4-associated caspase-1 activity
cleaves TRIF, resulting in inhibition of autophagy and pro-
duction of type I interferon production and consistent with
the bacteria using this as an evasion mechanism, blockage of
caspase-1 degradation of TRIF resulted in reduced IL-1b pro-
duction but increased autophagy and bacterial clearance in a
mouse model of P. aeruginosa infection [79,80].
Another major aspect that has likely contributed to the
contradictory data on the roles of autophagy in inflammation
reflects the emerging non-canonical and/or autophagy-
independent functions of components traditionally consid-
ered to be restricted to the autophagymachinery. The adaptor/
scaffold protein p62/SQSTM1 is one of the best characterised
exponents of this multi-functionality due to its multi-module
structure that contains PB1 (Phox and Bem1p-1), ZZ zinc
finger, Traf-binding (TB) Site and UBA (ubiquitin associated)domains that allow it to impact on a diverse range of cellular
processes, including inflammation, neurogenesis, osteoclas-
togenesis and T cell differentiation [81e85]. In relation to
inflammation, TLR induces upregulation and activation of p62,
which cooperates, with Traf6 to coordinate pro-inflammatory
cytokine secretion resulting from NF-kB activation. For
example, althoughTLR-signalling inkeratinocytes [86] induces
p62-dependent autophagy to negatively regulate inflamma-
tion, p62 is strongly upregulated and, by acting as an atypical
PKC scaffold (via its PB1 domain), generates a PKC 3/p62/Traf6
complex that promotes NF-kB activation to prime TLR-driven
inflammatory responses [86]. This role of p62 is in keeping
with its ability to activate NF-kB in autophagy-defective
tumour cells [87,88] and the critical actions of the PKC- 3/p62/
Traf6 complex in the activation of NF-kB in response to IL-1,
TNFa and RANKL [89,90]. Presumably reflecting this dual
functionality, by binding to Traf6 and interacting with its K63-
ubiquitin taggedsubstrates (via itsUBAdomain), p62 intersects
the two major cellular degradation pathways that, depending
on context, allows it to traffic targets to the proteasome or the
autophagosome for degradation.Autophagy and the adaptive immune response
Studies investigating the impact of autophagy genes, partic-
ularly ATG5 and ATG7, on the immune response have also
shown them toplay crucial roles in themaintenanceof normal
numbers of foetal haematopoietic stem cells, NK, CD4þ and
CD8þ T cells [10,68,91] as well as B cells and plasma cells, and
sustained production of immunoglobulin by the latter [92e94].
Autophagy also promotes maintenance of regulatory T cells
(Tregs). Indeed, inhibition of autophagy results in aberrant Th2
responses and intestinal inflammation, perhaps as a conse-
quence of the disruption of the autophagy-mediated counter-
regulation of the mTOR-regulated metabolic signalling that
determines Th lineage cell fate: thus, high mTOR activity/
anabolic (glycolytic) metabolism is associated with priming of
Th1, Th2 and Th17 responses whereas in addition to reflecting
the metabolic status of naive cells, the catabolic (fatty acid
oxidation) bias associated with the inhibition of mTOR pro-
motes maintenance of Tregs and memory cells [68,95e98].
Intriguingly, autophagy appears to be differentially regulated
in the various Th lineages with Th2 polarisation inducing
formation of more autophagosomes than in Th1 differentia-
tion, at least in vitro [68]. These findings that TCR signalling
induces autophagosome accumulation [98,99] appear rather at
odds with the high (counter-regulatory) mTOR signalling/
glycolytic signalling required for cell growth and rapid clonal
expansion. However, as the energy sensor, AMPK becomes
activated following TCR signalling [98,100], this should induce
autophagy, which may act to promote contraction of the im-
mune response and transition to the memory phase (condi-
tions where mTOR activity is low) [68,95e98]. Consistent with
this, autophagy downregulates TCR-coupled NF-kB activation
by the highly selective degradation of Bcl10 (but not its binding
partner Malt1) [101,102] via the TCR-driven K63-
polyubiquitination of Bcl10 and its subsequent binding to the
autophagy adaptor p62/SQSTM1. Reminiscent of the dual roles
of p62 in promoting TLR-stimulated NF-kB and resolving
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cytes andDCs [86,103], p62 binding to Bcl-10was required both
forNF-kB activation and its downregulation [101,102]: this dual
functionality perhaps suggests that the accumulation of
autophagosomes following TCR signalling reflects autophagic
flux blockade [103] to promote priming of responses, that is
alleviated by the fall in mTOR and rise in AMPK activation
allowing rapid induction of autophagic flux during the
contraction phase of the T cell response.Autophagy in inflammatory disease
In addition to its role in promoting maintenance of Treg
populations, autophagy also acts to maintain central toler-
ance [10] by promoting the expression of self-antigens byMHC
class II on thymic epithelial cells that is required for negative
selection of autoreactive thymocytes. Reflecting this, genetic
disruption of ATG5 in thymic epithelial cells results in
dysfunctional selection of certain MHC class-II restricted T-
cell specificities and autoimmunity [104]. Moreover, there are
clear links between the variants of autophagy genes and
(aberrant) immune responses [77,105] reflecting that loss of
ATG16L1 function in mice results in enhanced TLR-mediated
cytokine production by macrophages [77]. For example, poly-
morphisms in ATG16L1, such as the unstable T300A risk
variant, have been associated with susceptibility to Crohn's
disease, which is characterised by hyper-responsiveness to
the gut microbiota. This T300A variant has also been associ-
ated with higher mortality following haemopoietic stem cell
transplantation (HSCT), perhaps reflecting the ability of
autophagy to prevent such Graft Versus Host Disease (GVHD)
in animal models [106]. Likewise, GWAS (Genome Wide As-
sociation Studies) studies have linked several ATG5 poly-
morphisms with susceptibility to asthma and systemic lupus
erythematosus (SLE), but not rheumatoid arthritis (RA), at
least in the populations examined [107e110]. Furthermore,
certain mutations in the cystic fibrosis transmembrane
conductance receptor (CFTR) result in downregulation of
autophagy [111], perhaps contributing to the chronic lung in-
fections (P. aeruginosa and Burkholderia cenocepacia) associated
with this disease and it is therefore promising that treatment
with rapamycin may protect against this and suppress lung
inflammation [112]. Unfortunately, treatment of patients with
the antibiotic azithromycin, which had generally been
administered long-term to improve disease outcome by
reducing infection and chronic inflammation, was found to
exacerbate this suppression of autophagy and predispose
cystic fibrosis (CF) patients towards infection with non-
tuberculous Mycobacterium abscessus resulting in chronic
infection with this drug-resistant pathogen [113].
Advances in medicine, in concert with improved nutrition
and sanitation over the last century, have resulted in a dra-
matic increase in life-span: however, this has not necessarily
been accompanied by a corresponding increase in health and
well-being due to the accumulation of cellular damage asso-
ciated with the ageing process. This has been exacerbated by
themodernWestern life-style, that by incorporating a high fat
diet (HFD) results in the dysfunction of metabolic homeostatic
mechanisms, leading to age-associated co-morbidities such asType-2 diabetes (T2D), stroke and cardiovascular disease and
cancers [114]. Meta-analysis of gene signatures associated
with longevity and ageing of mouse hepatocytes [115], has
indicated that inflammatory genes (e.g. acute phase, comple-
ment, PRR and SLE-related) are upregulated whilst those
associated with metabolism and stress responses (e.g. xeno-
biotic (p450) metabolism as well as oxidative, mitochondrial
and Nrf2-regulated stress response/cytoprotective genes) are
downregulated during mid-life. By contrast, an inverse tran-
scriptional signaturewas observed in long-livedmice that also
validated their potential as biomarkers of ageing [115e117].
Certainly, chronic low-grade inflammation driven by (dys-
biosis {dysregulation of microbiota}-driven) activation of IL-
1R/TLR/MyD88 signalling and the NLRP3 inflammasome
appear to play key roles in regulating such inflamm-ageing
(chronic upregulation of inflammatory response with ageing)
[114,118e122]. Consequently, mTOR, which acts to integrate
metabolic and inflammatory signalling becomes dysregulated,
particularly under conditions of HFD, and promotes ER stress
and impairs insulin/IGF-1 signalling, increases glycolytic
metabolism and premature ageing of haemopoietic stem cells
(HSC) [74,123e125]. Thus, inflamm-ageing and dysregulated
mTOR are increasingly recognised as important integrated
triggers in the ageing process [74,114,123] and consistent with
this, genetic and pharmacological (e.g. by rapamycin) down-
regulation of mTOR has been shown to reduce ageing and
increase lifespan [74,123]. The protective, anti-ageing mecha-
nisms resulting from reduced mTOR signalling are not well
defined but increased autophagy [126] relieves ER stress and
maintains mitochondrial integrity in response to reactive ox-
ygen and nitrogen species (ROS; RNS) generated during dys-
regulated glucose metabolism and energy homeostasis [127].
Supporting this key role for autophagy, short-lived S. cer-
evisiae, Caenorhabditis elegans and Drosophila melanogaster mu-
tants exhibit defects in autophagy [128] and mice with brain-
specific ATG5 or ATG7 deletion, exhibit reduced lifespan
[129]. Certainly, expression of the autophagy machinery (e.g.
ATG5/7, Beclin 1 and Sirtuin 1) declines with age and this loss
of autophagy function appears to impact directly on various
parameters associated the ageing process, notably the accu-
mulation of toxic protein aggregates, decreasedmitochondrial
function, increased (stress-induced) cell death, stem cell loss
and induction of cellular senescence [128].Autophagy: a target with therapeutic potential
In addition to its role in regulating infection, inflammation
and ageing, as well as the inflamm-ageing that underpins
ageing-associated comorbidities like obesity and cardiovas-
cular disease [128,130], autophagy has been implicated both in
protecting against and promoting a wide range of diseases,
including neurodegenerative and muscle disorders and can-
cers [73,130e132]. Indeed, the intense focus on developing
novel therapies based on modulating autophagy reflects the
wealth of evidence that genetic modifications of autophagy
genes in mice and deficiencies/polymorphisms of these genes
in humans can be correlated with human illnesses encom-
passing inflammatory diseases such as asthma, COPD and
autoimmunity (inflammatory bowel diseases [IBD] and SLE)
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(motor neuropathies, Parkinson's, Huntington's, dementia),
diabetes, atherosclerosis and cancers (breast, ovarian, pros-
trate, colorectal, lung and brain) as well as susceptibility to
various infections (Mycobacterium tuberculosis, Mycobacterium
leprae, Salmonella typhi and Salmonella paratyphi). Promisingly,
therefore, gene therapy involving ATG7, Tfeb and BECN1 has
resulted in amelioration of diseases including obesity, Par-
kinson's and Alzheimer's diseases and cystic fibrosis inmouse
models. Moreover, a number of commonly used drugs can
induce autophagy by their ability to target levels of IP3/Ca
2þ
(Carbamazepine, Lithium, Verapamil); cAMP (Clonidine) and
AMPK/mTORC1 (Metformin, Statins, Rapamycin): this raises
the exciting possibility of their potential repurposing for dis-
eases associated with defects in the regulation of autophagy
(rather than in the autophagy machinery, per se) and indeed,
mTOR inhibitors and Statins have already been repurposed for
treatment of neurodegenerative diseases and infection with
M. tuberculosis, respectively [130e132]. This rational approach
to repurposing is complemented by intensive screening and
development of small molecule regulators of autophagy for
novel drug development [131e134].Fig. 2 TLR4 signalling: subversion of autophagic flux by ES-62 pro
TLR4/MD2 signalling induces an early MyD88/Mal phase of NF-kB
-b, followed by a more prolonged TRAM/TRIF endosomal signallin
increased due to blockage of autophagic flux, allowing it to further
resulting in pro-inflammatory cytokine production. During resolu
feedback inhibition mechanism. Panel B. ES-62 specifically targets
transducers required for full TLR activation: this is achieved by in
p62 and LC3-II upon inhibition of autophagolysosomal degradatio
p62-PKC 3-mediated NF-kB activation, this results in dampening oHowever, depending on the context, autophagy can be
both cytoprotective and cytotoxic: thus, whilst its ability to
promote cell death may be desirable in combating certain
cancers, this could contribute to pathogenesis in a host of
disorders ranging from diabetes to ischemic brain damage.
Moreover, therapeutic induction of autophagy could poten-
tially leave patients open to catastrophic infection. Thus, an
alternative and safer approach may be to harness the thera-
peutic potential of organisms such as parasitic helminths (and
in particular their secreted immunomodulators) that by acting
to dampen down host inflammation and limit tissue pathol-
ogy to promote both parasitic worm and host survival
[135,136], appear to serendipitously suppress allergic and
autoimmune inflammatory diseases as evidenced by the clear
inverse relationship between the incidence of these parasitic
worms and the prevalence of chronic inflammatory disorders
globally [137e140]. The ability of these parasites to protect
against metabolic syndrome and obesity [141e148] is also
increasingly recognised. Perhaps pertinently, given that
obesity and autoimmunity are reciprocal risk factors that
impact on ageing and associated co-morbidities, evidence is
also emerging that (at least some) of these anti-inflammatorymotes homeostatic resetting of inflammation. Panel A. LPS-
activation via the rapid proteosomal degradation of IkB-a and
g phase during which the expression of p62 is progressively
stimulate, via a Traf6-p62-PKC 3complex, activation of NF-kB
tion of inflammation, autophagic flux provides a negative
the autophagolysosomal degradation of PKCd, and Traf6, key
duction of autophagic flux (evidenced by the accumulation of
n). Together with the accompanying suppression of Traf6-
f LPS-induced cytokine production.
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autophagy to suppress (aberrant) inflammation [103,149,150].
Thus, we have shown that ES-62, a phosphorylcholine (PC)-
containing immunomodulatory glycoprotein from the filarial
nematode Acanthocheilonema viteae, which exhibits protection
against disease in mouse models of allergic and autoimmune
disease [135,139,150], can homeostatically reset inflammatory
responses by partially downregulating MyD88 expression to
subvert TLR signalling in effector cells of both innate and
adaptive immunity [150e154]. ES-62 appears to do this by
inducing highly selective autophagolysosomal degradation of
MyD88 (but not its binding partner Mal) and, depending on the
cell type, other TLR-associated signalling elements like PKC-a
and -d (mast cells) or PKC-d and Traf6 (DCs) [103,150,151,155].
Specifically, whilst LPS/TLR4 signalling strongly upregulates
p62 and LC3, this appears to be associated with a block in
autophagic flux, allowing p62 to promote NF-kB-mediated
cytokine responses: by contrast, ES-62 induces a low level of
ATG7-dependent autophagic flux to sequester and degrade
Traf6 and PKC-d to dampen such LPS-driven pro-inflamma-
tory responses [Fig. 2].
Importantly, ES-62 appears to preferentially mediate its
effects during conditions of inflammation; for example, ES-
62-induced autophagolysosomal degradation of MyD88 in
DCs is enhanced in the presence of GM-CSF [103,150], a
cytokine that plays important roles in chronic, MyD88-
dependent inflammation and pathologies associated with
metabolic syndrome [156]. In this way, ES-62 does not block
induction of inflammatory responses necessary to combat
infection but rather acts in a homeostatic way to prevent
perpetuation of chronic hyper-inflammation [103,150].
Reflecting this, we have obtained microarray data ([135] and
unpublished) showing that in synovial membranes from RA,
but not osteoarthritis, patients, whilst ES-62 downregulates
LPS-stimulated levels of the insulin signalling pathway
(IGFR2, IRS2 and IGF-1) and inflammation-associated genes
such as TLR4, FcgRIIa, C1q and C3aR, chemokines CCL3 and
11 and caspase-1, it upregulates anti-oxidant/cytoprotective
genes (including glutathione s-transferase, methionine
adenosyltransferase, histamine methyltransferase and suc-
cinyl CoA ligase), several of which have been investigated for
their impact in long-lived Ames mice [157,158]. This
apparent inverse control of inflammation-promoting genes
and anti-oxidant/cytoprotective pathways may suggest that
in conjunction with its ability to suppress PI3K/AKT [159]
(and hence presumably mTOR) signalling, induction of se-
lective autophagy may be a central tenet of ES-62 protection.
Intriguingly, therefore, a small molecule analogue of ES-62,
termed 11a, is protective against the development of
collagen-induced arthritis in a mouse model of RA, by virtue
of its ability to downregulate MyD88 and NLRP3 expression
and consequent IL-1b production, in an Nrf-2-dependent
manner [160]. Given the role of p62/SQSTM1 in autophago-
lysosomal degradation of KEAP1, the negative regulator of
Nrf-2, it is therefore tempting to speculate that the protective
effects of ES-62 and a small molecule analogue SMA-11a
involve induction of selective autophagy to effect differen-
tial degradation of key pathogenic signals and upregulation
of cytoprotective pathways to effect inflammation resolution
and tissue repair. Harnessing of this homeostatic regulatorymechanism presumably evolved to promote parasite sur-
vival but may now be exploited therapeutically.
Finally, returning to the theme of food intake, an emerging
factor is the recognition that dietary restriction, nutritional
factors (e.g. caffeine or vitamin-D) and exercise may exert
their health-promoting effects, at least in part by promoting
autophagy [130]. Thus, autophagy appears to be essential to
the extension of lifespan in C. elegans afforded by dietary re-
striction [161], as is the caffeine-induced reduction of steatosis
in mice with non-alcoholic liver disease [162] and even the
effects of exercise that counteract HFD-induced diabetes in
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